DEVELOPMENT AND CLINICAL EFFECTIVENESS OF ANTIANDROGENS IN THE TREATMENT OF ADVANCED PROSTATE CANCER
Prostate cancer (PCa) is a hormonsensitive tumor. Due to the discovery of the androgen receptor (AR) it became possible to implement the antiandrogens as drugs blocking testosterone Binding to the AR into routine clinical practice. There have been discovered several generations of the antiandrogens...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
Remedium Group LLC
2016-12-01
|
| Series: | Медицинский совет |
| Subjects: | |
| Online Access: | https://www.med-sovet.pro/jour/article/view/1402 |
| _version_ | 1797841390043922432 |
|---|---|
| author | S. V. MISHUGIN A. A. GRITSKEVICH I. G. RUSAKOV |
| author_facet | S. V. MISHUGIN A. A. GRITSKEVICH I. G. RUSAKOV |
| author_sort | S. V. MISHUGIN |
| collection | DOAJ |
| description | Prostate cancer (PCa) is a hormonsensitive tumor. Due to the discovery of the androgen receptor (AR) it became possible to implement the antiandrogens as drugs blocking testosterone Binding to the AR into routine clinical practice. There have been discovered several generations of the antiandrogens over the years and the possibility of using these drugs in clinical practice has significantly changed. First generations of the antiandrogens (cyproterone, flutamid, bicalutamid) are used mainly for the treatment of advanced hormonsensitive PCa in combination with castration therapy. However these drugs do not increase survival in patients with PCa and are not indicated in terms of castration resistant PCa. Discovery of the enzalutamide (antiandrogen of 2’d generation), acting on the nuclear level of the tumor cell, allowed to increase significantly survival in patients with metastatic castration-resistant prostate cancer (mCRPC) and improve treatment results in patients with mCRPC. At the moment enzalutamide is being studied in combination with castration therapy in patients with hormonsensitive PCa. |
| first_indexed | 2024-04-09T16:31:11Z |
| format | Article |
| id | doaj.art-ccc336ae36df4d01be13a8184eb76018 |
| institution | Directory Open Access Journal |
| issn | 2079-701X 2658-5790 |
| language | Russian |
| last_indexed | 2024-04-09T16:31:11Z |
| publishDate | 2016-12-01 |
| publisher | Remedium Group LLC |
| record_format | Article |
| series | Медицинский совет |
| spelling | doaj.art-ccc336ae36df4d01be13a8184eb760182023-04-23T06:57:07ZrusRemedium Group LLCМедицинский совет2079-701X2658-57902016-12-01010343710.21518/2079-701X-2016-10-34-371399DEVELOPMENT AND CLINICAL EFFECTIVENESS OF ANTIANDROGENS IN THE TREATMENT OF ADVANCED PROSTATE CANCERS. V. MISHUGIN0A. A. GRITSKEVICH1I. G. RUSAKOV2City Clinical Hospital №57Vishnevsky Institute of SurgeryМНИОИ им. П.А. ГерценаProstate cancer (PCa) is a hormonsensitive tumor. Due to the discovery of the androgen receptor (AR) it became possible to implement the antiandrogens as drugs blocking testosterone Binding to the AR into routine clinical practice. There have been discovered several generations of the antiandrogens over the years and the possibility of using these drugs in clinical practice has significantly changed. First generations of the antiandrogens (cyproterone, flutamid, bicalutamid) are used mainly for the treatment of advanced hormonsensitive PCa in combination with castration therapy. However these drugs do not increase survival in patients with PCa and are not indicated in terms of castration resistant PCa. Discovery of the enzalutamide (antiandrogen of 2’d generation), acting on the nuclear level of the tumor cell, allowed to increase significantly survival in patients with metastatic castration-resistant prostate cancer (mCRPC) and improve treatment results in patients with mCRPC. At the moment enzalutamide is being studied in combination with castration therapy in patients with hormonsensitive PCa.https://www.med-sovet.pro/jour/article/view/1402metastatic castration-resistant prostate cancerandrogen receptorantiandrogenscyproteronflutamidbicalutamidnilutamidenzalutamid |
| spellingShingle | S. V. MISHUGIN A. A. GRITSKEVICH I. G. RUSAKOV DEVELOPMENT AND CLINICAL EFFECTIVENESS OF ANTIANDROGENS IN THE TREATMENT OF ADVANCED PROSTATE CANCER Медицинский совет metastatic castration-resistant prostate cancer androgen receptor antiandrogens cyproteron flutamid bicalutamid nilutamid enzalutamid |
| title | DEVELOPMENT AND CLINICAL EFFECTIVENESS OF ANTIANDROGENS IN THE TREATMENT OF ADVANCED PROSTATE CANCER |
| title_full | DEVELOPMENT AND CLINICAL EFFECTIVENESS OF ANTIANDROGENS IN THE TREATMENT OF ADVANCED PROSTATE CANCER |
| title_fullStr | DEVELOPMENT AND CLINICAL EFFECTIVENESS OF ANTIANDROGENS IN THE TREATMENT OF ADVANCED PROSTATE CANCER |
| title_full_unstemmed | DEVELOPMENT AND CLINICAL EFFECTIVENESS OF ANTIANDROGENS IN THE TREATMENT OF ADVANCED PROSTATE CANCER |
| title_short | DEVELOPMENT AND CLINICAL EFFECTIVENESS OF ANTIANDROGENS IN THE TREATMENT OF ADVANCED PROSTATE CANCER |
| title_sort | development and clinical effectiveness of antiandrogens in the treatment of advanced prostate cancer |
| topic | metastatic castration-resistant prostate cancer androgen receptor antiandrogens cyproteron flutamid bicalutamid nilutamid enzalutamid |
| url | https://www.med-sovet.pro/jour/article/view/1402 |
| work_keys_str_mv | AT svmishugin developmentandclinicaleffectivenessofantiandrogensinthetreatmentofadvancedprostatecancer AT aagritskevich developmentandclinicaleffectivenessofantiandrogensinthetreatmentofadvancedprostatecancer AT igrusakov developmentandclinicaleffectivenessofantiandrogensinthetreatmentofadvancedprostatecancer |